Sepracor - Scientific Abstracts : XOPENEX(R) (levalbuterol)

1. Andrews T, McGintee E, Tyler L, Mittal M, Chew A, Pawlowski N, Zorc J. Efficacy of high-dose continuous nebulized levalbuterol for pediatric status asthmaticus (Abstract). JACI 2007;(1):S244.

2. Duru EA, Parks JL, Calhoun WJ, Ameredes BT. Modulation of effects of albuterol enantiomers on IL-6 release in human airway smooth muscle cells as a function of cellstimulation (Abstract). JACI 2007;(1):S296.

3. McVicar WK, Bonasia P, Ong S. Compatability of levalbuteol inhalation solution mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium (Abstract). JACI 2007;(1):S1.

4. McVicar WK, Korenblat PE, Pleskow WW, Rees Wc, Parsey M, Tripp K, Baumgartner RA. Cumulative dose tolerability study of levalbuterol HFA and racemic albuterol HFA in patients with asthma (Abstract). Presented as a poster at the Southwest Allergy Fourm, January 17 - 21, 2007 in Puerta Vallarta, Mexico.

6. Pearlman DS, Rees W, Huang H, Schaefer K, Andrews W. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm (Abstract). Presented as a poster at Western Society of Allergy, Asthma, & Immunology 2007 in Maui, Hawaii.

2006 XOPENEX (levalbuterol) Abstracts

1. Agrawal DK, Cheng G, Kelbe PW, Bakale R. Class-specific effect of the enantiomers of b2-agonists on the activation of nuclear factor kb in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

2. Agrawal DK, Kim MJ, Kelbe PW, Bakale R. Class-specificity of the binding of [3H](S)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A467.

3. Agrawal DK, Cheng G, Kelbe P. Masking of corticosteroid-induced inhibition of NF-kb activation by (S)-albuterol in human airway smooth muscle cells and human blood lymphocytes (Abstract). JACI 2006, 117[2], S140.

4. Andrews T, McGintee E, Tyler L, Mittal M, Pawlowski NA, Zorc JJ. Safety of high-dose continuous levalbuterol (Abstract). JACI 2006, 117[2], S196.

5. Berger WE, Milgrom H, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of the Western Society of Allergy, Asthma, & Immunology. 2006.

6. Cheng G, Kelbe PW, Agrawal DK. Induction of nuclear factor kb activity and masking of the beneficial effect of corticosteroid by (s)-albuterol in human airway smooth muscle cells (Abstract). Proceedings of the American Thoracic Society 2006;3:A77.

7. Cleary JC, Karmazyn Y, Mogayzel PJ, Laube BL. Chronic administration of levalbuterol or racemic albuterol does not enhance mucociliary clearance in healthy subjects (Abstract). Proceedings of the American Thoracic Society 2006;3:A78.

8. Finn PW, Amirifeli S, He H, Campo M, Ferrada M, Barone L, Perkins D. Albuterol in an allergic murine model (Abstract). Proceedings of the American Thoracic Society 2006;3:A346.

9. Frieri M, Capetandes A. (R)-, but not (S)-, enantiomers of beta2 agonists inhibit IL-8 secretion by rsv antigen-stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S318. 2006.

10. Mendes ES, Campos MA, Wanner A. A novel mechanism of glucocorticoid-adrenergic interaction in the regulation of airway blood flow (Abstract). Proceedings of the American Thoracic Society 2006;3:A688.

11. Milgrom H, Berger WE, Kim K, Tripp K, Maier G, Baumgartner R. Levalbuterol HFA MDI for treatment of pediatric asthma: a double-blind, randomized, placebo- and active- controlled trial (Abstract). Annual Meeting of Southwest Allergy Forum . 2006.

12. Morris GF, Johnson AR, Perry LA, Brody AR. Activation of the human proliferating cell nuclear antigen (PCNA) promoter in vivo and in cell culture by stereoisomers of albuterol (Abstract). Proceedings of the American Thoracic Society 2006;3:A697.

13. Puglisi G, Capetandes A, Frieri M. 10-6M (RR)-formoterol, but not (SS)-formotrol or (S)/(R)-albuterol, inhibits rantes secretion by rsv antigen- stimulated confluent human alveolar epithelial cells (cA549) (Abstract). JACI 117[2], S155. 2006.

14. Schulman ES, Nishi H, Pelleg A. Differential effects of albuterol stereoisomers on human lung mast cell mediator release (Abstract). Proceedings of the American Thoracic Society 2006;3:A589.

2005 XOPENEX (levalbuterol) Abstracts

1. Chorley BN, Adler KB. β2-adrenergic receptor activation with (r)-albuterol attenuates granulocyte macrophage colony stimulating factor (GM-CSF) expression via an iNOS-mediated pathway in human brochial epithelial cells in vitro. Proceedings of the American Thoracic Society 2005; 2:A757 (Abstract).

2. Codispoti C, Calhoun WJ, Ameredes BT. Eotaxin release from human airway smooth muscle cells treated with albuterol enantiomers. JACI 2005, 115(2):S48 (Abstract).

3. Donohue JF, Parsey M, Andrews C, D'Urzo T, Sharma S, Schaefer K, Claus R, Baumgartner R. Levalbuterol in the treatment of patients with Chronic Obstructive Pulmonary disease. CHEST 2005;128(4):260S. (Abstract).

4. Emerman C, Nowak R, Hanania N, Koester J, Claus R, Anderson A, Roach J, McVicar W, Hanrahan J. Fev1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Aspen Allergy Conference, July 26 - 30, 2005, Aspen, CO (Abstract).

5. Frieri M, Capetandes A. (S)-albuterol increases CysLT1R expression and VEGF mRNA by normal human lung fibroblasts (NHLF). JACI 2005, 115(2):S14 (Abstract).

6. Frieri M, Capetandes A. Effect of (s)-albuterol vs (r)-albuterol on vascular endothelial growth factor, basic fibroblast growth factor and fibronectin secretion from normal human fibroblasts and myofibroblasts. Ann Allergy Asthma Immunol 2005; 1:185 (Abstract).

7. Hanania N, Emerman C, Nowak R, Claus R, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Southwestern Allergy Forum 2005, Puerta Vallarta, Mexico (Abstract).

8. Hanania N, Emerman C, Nowak R, Claus R, Snider ME, Varga J, Andrews W, McVicar W, Hanrahan JP. FEV1 response to levalbuterol vs racemic albuterol in acute severe asthma. Presented at the Annual Meeting of the Western Society of Allergy, Asthma, & Immunology 2005, Hawaii (Abstract).

9. Ozminkowski RJ, Long SR, Wang S, Barry N, Schaefer K. Healthcare utilization for elderly Medicaid patients treated with nebulized levalbuterol (LEV) or racemic albuterol (RAC). Proceedings of the American Thoracic Society 2005; 2:A925 (Abstract).

10. Perry A, Persinger R, Schwartz Y, Chang M, Wu R. (R)- and (S)-albuterol exhibit differential effects on mucociliary transport and mucin secretion. Presented at the Gordon Conference on Cilia, Mucus & Mucociliary Interactions, February 27 - March 4, 2005, Buellton, CA (Abstract).

11. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Breakthrough treatment rates during a conversion to levalbuterol, tiotropium and breath actuated nebulizers. CHEST 2005; 128(4):259S. (Abstract).

12. Pikarsky RS, Acevedo RA, Farrell T, Fascia W. Economic impact resulting from a conversion to levalbuterol every six to eight hours. CHEST 2005;128(4):259S. (Abstract).

13. Puglisi G, Horne N, Huang YC, Frieri M. Transforming growth factor beta 1 (TGF-β1) production and expression from ragweed stimulated human alveolar epithelial cells (A549): modulation by budesonide, formoterol, and levalbuterol. Ann Allergy Asthma Immunol 2005; 1:165 (Abstract).

14. Raissy HH, Harkins M, Esparham A, Kelly HW. A double-blind, placebo-controlled crossover comparison of the dose-response to levalbuterol for reversing methacholine-induced bronchoconstriction with and without pretreatment with (s)-albuterol. Proceedings of the American Thoracic Society 2005; 2:A356. (Abstract).

15. Rance K, Trent C. Improved asthma outcomes achieved through a synergistic relationship between education and pharmacology in a high-risk population. Presented at the National Association of Pediatric Nurse Practitioners Annual Meeting, March 31 - April 3, 2005, Phoenix, AZ (Poster).